Great Lakes Advisors LLC Lowers Holdings in Astrana Health, Inc. (NASDAQ:ASTH)

Great Lakes Advisors LLC decreased its holdings in Astrana Health, Inc. (NASDAQ:ASTH) by 20.6% in the 4th quarter, HoldingsChannel reports. The firm owned 32,101 shares of the company’s stock after selling 8,346 shares during the quarter. Great Lakes Advisors LLC’s holdings in Astrana Health were worth $1,012,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Amalgamated Bank acquired a new stake in Astrana Health in the third quarter valued at approximately $713,000. Principal Financial Group Inc. acquired a new stake in Astrana Health in the third quarter valued at approximately $13,383,000. Victory Capital Management Inc. acquired a new stake in Astrana Health in the third quarter valued at approximately $2,596,000. KBC Group NV acquired a new stake in Astrana Health in the third quarter valued at approximately $70,000. Finally, Royce & Associates LP acquired a new stake in Astrana Health in the third quarter valued at approximately $6,661,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Performance

Shares of ASTH opened at $29.34 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The stock has a market capitalization of $1.65 billion, a P/E ratio of 22.57, a P/E/G ratio of 1.37 and a beta of 1.30. The company’s fifty day moving average is $33.96 and its two-hundred day moving average is $43.10. Astrana Health, Inc. has a 1 year low of $23.12 and a 1 year high of $63.20.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. On average, sell-side analysts predict that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

ASTH has been the topic of several analyst reports. Macquarie raised shares of Astrana Health to a “hold” rating in a report on Monday, December 16th. Bank of America reduced their target price on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. Truist Financial cut their price objective on shares of Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, January 13th. Stifel Nicolaus cut their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, February 20th. Finally, Robert W. Baird cut their price objective on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $56.83.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.